What Happens After a Non-Negative DOT Drug Test: The Collector’s Role Explained

Once you seal that specimen bag and hand it off, your collection is done. But the process isn’t — and understanding what happens next makes you a better, more defensible collector.

Most collectors know their piece of the DOT drug testing process. Fewer understand what happens after the specimen leaves the collection site — who reviews it, what triggers a non-negative DOT drug test result, how the Medical Review Officer enters the picture, and what that means for your documentation. This article walks through the full chain, step by step, from initial screening to final employer notification.

1. The Collector’s Job Ends at the Lab — But You Need to Know What Comes Next

Your legal obligation as a DOT urine collector ends when you properly seal the specimen, complete the chain of custody form (CCF), and hand the package off to the courier or laboratory. You are not part of the testing or reporting process that follows.

But collectors who understand the downstream process make fewer critical errors. Knowing what the Medical Review Officer looks for on your CCF — and what triggers a non-negative result review — changes how you approach documentation. It’s not abstract knowledge. It’s professional protection.

2. Step 1: Initial Screen at the Lab (Immunoassay)

Every DOT urine specimen goes to a SAMHSA-certified laboratory — a facility certified under the Department of Health and Human Services (HHS) National Laboratory Certification Program. No other lab is permitted for DOT-regulated testing.

At the lab, the A bottle (primary specimen) first goes through an immunoassay screen. This initial test checks for the presence of drug metabolites across five federally mandated categories:

• Marijuana metabolites (THC-COOH)
• Cocaine metabolites (benzoylecgonine)
• Opioids (including heroin, oxycodone, hydrocodone)
• Amphetamines (amphetamine and methamphetamine)
• Phencyclidine (PCP)

If the screen is negative: The result is reported as “Negative.” The process ends here. The employer receives a negative result and the donor is cleared.

If the screen shows reactivity: The specimen moves to confirmatory testing. At this stage, the result is classified as a non-negative — not yet a confirmed positive. This distinction matters enormously. A non-negative DOT drug test result simply means the immunoassay screen detected something that needs further analysis. It is not a final result. No employer is notified at this stage.

3. Step 2: Confirmatory Testing (GC/MS or LC-MS/MS)

Any specimen flagged as non-negative on the immunoassay screen moves to confirmatory testing using gas chromatography–mass spectrometry (GC/MS) or liquid chromatography–tandem mass spectrometry (LC-MS/MS). These methods are highly specific — they identify the exact drug compound and confirm whether the initial screen was a true positive or a false positive (49 CFR § 40.91).

The lab also runs validity testing on the specimen. Under 49 CFR Part 40 Subpart F (§§ 40.91–40.101), this checks for:

• Substitution — creatinine below 2 mg/dL plus specific gravity below 1.0010 (49 CFR § 40.91(c)), indicating the specimen is not consistent with human urine
• Adulteration — pH outside the range of 3–11 (49 CFR § 40.91(b)), or presence of a foreign substance that interferes with testing
• Specimen insufficiency — less than 30 mL in the primary specimen bottle, making testing impossible

After confirmatory testing, the lab reports one of five possible outcomes under Part 40: Positive, Negative, Substituted, Adulterated, or Invalid. Each has a specific regulatory meaning and triggers a distinct pathway at the MRO level. A result is not reported to the employer until it passes through MRO review.

4. Step 3: The MRO Review

The Medical Review Officer (MRO) is a licensed physician who has completed specialized training in the DOT drug testing program. No confirmed positive or validity finding goes to an employer without passing through MRO review first (49 CFR §§ 40.121–40.165). This is one of the fundamental safeguards in the system.

Here is how the DOT drug test MRO review process works:

1. 1

   The lab transmits the confirmed positive or validity finding to the MRO, along with a copy of the CCF (Copy 2 — the MRO’s copy).

2. 2

   The MRO contacts the donor — directly, not through the employer — to review whether there is a legitimate medical explanation for the result. A valid prescription for an opioid, for example, may explain an opioid-positive screen.

3. 3

   If the donor provides a valid explanation that the MRO accepts, the MRO may report the result as Negative to the employer. The positive is not reported.

4. 4

   If the donor provides no valid explanation — or cannot be reached within the required timeframe — the MRO reports the result as Positive, Refusal to Test, Cancelled, or another final determination to the employer’s Designated Employer Representative (DER).

The collector plays no role in the MRO review process and is not informed of the final result. But the MRO depends entirely on what you submitted in the collection process — specifically, the CCF.

5. What the Collector’s Documentation Must Show for the MRO

The CCF is the MRO’s primary paper trail for the collection. When a confirmed positive or validity finding arrives from the lab, the MRO reviews the CCF to verify the collection was conducted properly before proceeding with the donor interview.

Here is what the MRO looks for:

• Copy 1 (lab copy) and Copy 2 (MRO copy) must be complete and legible. No white-out, no missing fields, no ink corrections that aren’t initialed and dated. Any ambiguity in the CCF becomes a problem the MRO has to resolve.
• The collector’s signature, date/time, and specimen ID must match across all CCF copies. If the specimen ID on Copy 1 doesn’t match Copy 2, or the date is inconsistent, the MRO must flag it.
• A “fatal flaw” on the CCF = the MRO cannot process the result. Under 49 CFR Part 40, certain errors are so serious that the specimen must be cancelled and the employer must send the donor for a recollection. Fatal flaws include a missing collector signature, wrong specimen ID, or use of a non-federal form. If you are named as the collector, your error is documented in the discrepancy report.

6. Agency-Specific Considerations: FMCSA, FRA, FAA, PHMSA

The MRO review process is governed by 49 CFR Part 40 across all DOT-regulated agencies — but what happens after the MRO reports a confirmed positive varies by agency. Collectors who work across industries should understand these differences.

7. What a Collector Should Never Do

The post-collection process creates a specific set of boundaries for collectors. These are not suggestions — they are federal protocol. Violating them exposes you to removal from the qualified collector list and legal liability.

• Never tell the donor the result. You don’t have it. And even if you somehow did, reporting results to the donor is the exclusive job of the MRO — never the collector. Any result disclosure by a collector is a regulatory violation.

• Never speculate about whether a specimen will test positive. You saw the collection. You are not qualified to predict the outcome of laboratory analysis, and any comment you make could create a legal problem for you, the employer, or the donor.

• Never release CCF copies to the donor beyond Copy 5. Copy 5 is the donor’s copy — it is theirs, and you must give it to them before they leave. That is it. No other copies go to the donor. Copy 1 goes to the lab. Copy 2 goes to the MRO. Copies 3 and 4 go to the employer and collection site. Only Copy 5 belongs to the donor.

• Never contact the lab directly on the donor’s behalf. The donor has the right to request a split specimen retest through the MRO — not through the collector. If a donor asks you to call the lab about their specimen, the correct answer is no.

• If the donor asks “did I pass?” — give them the standard answer: “Results are reported to your employer through the Medical Review Officer. I’m not part of that process.” This is not evasion. It is the accurate answer, and it protects everyone.

8. Why This Knowledge Makes You a Better Collector

Collectors who understand what happens after a non-negative DOT drug test result make fewer fatal flaws on the CCF. That’s not a coincidence — it’s cause and effect. When you know the MRO is going to scrutinize every field of Copy 2, you treat the form differently than if it just feels like paperwork.

Knowing what the MRO is looking for also means you protect your own documentation and professional standing. If a discrepancy report ever names you as the collector of record, your CCF is the first thing reviewed. A clean, complete, legible CCF is your defense.

There’s also a hiring dimension. Some employers and TPAs specifically ask collectors if they understand the MRO review process during interviews or contract vetting. Collectors who can describe the DOT drug test process after collection — not just the collection steps themselves — stand out. Understanding the full system from pre-collection setup through confirmed positive dot test reporting is what differentiates a credentialed professional from someone who took a weekend course and stopped there.

If you’re ready to build that kind of depth — whether you’re starting out or want to fill in gaps in your knowledge — the path is shorter than most people expect. How to become a DOT collector walks through the federal requirements, and once you’re certified, how to start a DOT collection business shows you how to take that certification into independent practice.

For a deeper look at the specific collection scenarios — including observed collections that are required after certain non-negative or invalid results — our certification course covers the complete chain from pre-collection setup to MRO handoff.